BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

701 related articles for article (PubMed ID: 8402652)

  • 1. Evidence for oligoclonal T-cell response in a metastasis of renal cell carcinoma responding to vaccination with autologous tumor cells and transfer of in vitro-sensitized vaccine-draining lymph node lymphocytes.
    Weidmann E; Logan TF; Yasumura S; Kirkwood JM; Trucco M; Whiteside TL
    Cancer Res; 1993 Oct; 53(20):4745-9. PubMed ID: 8402652
    [TBL] [Abstract][Full Text] [Related]  

  • 2. The T-cell receptor V beta gene usage in tumor-infiltrating lymphocytes and blood of patients with hepatocellular carcinoma.
    Weidmann E; Whiteside TL; Giorda R; Herberman RB; Trucco M
    Cancer Res; 1992 Nov; 52(21):5913-20. PubMed ID: 1382847
    [TBL] [Abstract][Full Text] [Related]  

  • 3. In vivo local expansion of clonal T cell subpopulations in renal cell carcinoma.
    Gaudin C; Dietrich PY; Robache S; Guillard M; Escudier B; Lacombe MJ; Kumar A; Triebel F; Caignard A
    Cancer Res; 1995 Feb; 55(3):685-90. PubMed ID: 7834641
    [TBL] [Abstract][Full Text] [Related]  

  • 4. T-cell receptor gene-modified T cells with shared renal cell carcinoma specificity for adoptive T-cell therapy.
    Leisegang M; Turqueti-Neves A; Engels B; Blankenstein T; Schendel DJ; Uckert W; Noessner E
    Clin Cancer Res; 2010 Apr; 16(8):2333-43. PubMed ID: 20371691
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Selective lysis of autologous tumor cells by recurrent gamma delta tumor-infiltrating lymphocytes from renal carcinoma.
    Choudhary A; Davodeau F; Moreau A; Peyrat MA; Bonneville M; Jotereau F
    J Immunol; 1995 Apr; 154(8):3932-40. PubMed ID: 7706731
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Interleukin-2 expanded lymphocytes from lymph node and tumor biopsies of human renal cell carcinoma, breast and ovarian cancer.
    Bouet-Toussaint F; Genetel N; Rioux-Leclercq N; Bansard JY; Levêque J; Guillé F; Patard JJ; Lesimple T; Catros-Quemener V
    Eur Cytokine Netw; 2000 Jun; 11(2):217-24. PubMed ID: 10903800
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical observations on adoptive immunotherapy with vaccine-primed T-lymphocytes secondarily sensitized to tumor in vitro.
    Chang AE; Yoshizawa H; Sakai K; Cameron MJ; Sondak VK; Shu S
    Cancer Res; 1993 Mar; 53(5):1043-50. PubMed ID: 8439951
    [TBL] [Abstract][Full Text] [Related]  

  • 8. T cell functions of IL-2-activated tumor-infiltrating lymphocytes from renal cell carcinoma.
    Morita T; Salmeron MA; Hayakawa K; Swanson DA; von Eschenbach AC; Itoh K
    Reg Immunol; 1992; 4(4):225-35. PubMed ID: 1476875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. T-cells infiltrating renal cell carcinoma display a poor proliferative response even though they can produce interleukin 2 and express interleukin 2 receptors.
    Alexander JP; Kudoh S; Melsop KA; Hamilton TA; Edinger MG; Tubbs RR; Sica D; Tuason L; Klein E; Bukowski RM
    Cancer Res; 1993 Mar; 53(6):1380-7. PubMed ID: 8443817
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Characteristics and in vivo homing of long-term T-cell lines and clones derived from tumor-draining lymph nodes.
    Matsumura T; Sussman JJ; Krinock RA; Chang AE; Shu S
    Cancer Res; 1994 May; 54(10):2744-50. PubMed ID: 8168105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. T cell receptor V beta 2 and V beta 6 mediate tumor-specific cytotoxicity by tumor-infiltrating lymphocytes in ovarian cancer.
    Peoples GE; Davey MP; Goedegebuure PS; Schoof DD; Eberlein TJ
    J Immunol; 1993 Nov; 151(10):5472-80. PubMed ID: 8228239
    [TBL] [Abstract][Full Text] [Related]  

  • 12. T-cell receptor repertoire in matched MART-1 peptide-stimulated peripheral blood lymphocytes and tumor-infiltrating lymphocytes.
    Cole DJ; Wilson MC; Rivoltini L; Custer M; Nishimura MI
    Cancer Res; 1997 Dec; 57(23):5320-7. PubMed ID: 9393756
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Analysis of T cell receptor alpha beta variability in tumor-infiltrating lymphocytes in primary and metastatic melanoma.
    Zeuthen J; Birck A; Straten PT
    Arch Immunol Ther Exp (Warsz); 1995; 43(2):123-33. PubMed ID: 8744727
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Expansion of murine T cells bearing a unique T cell receptor beta-chain in Friend virus-induced tumor in situ.
    Suzuki M; Koseki H; Mizutani Y; Kuribayashi K; Kanno M; Taniguchi M
    J Immunol; 1992 May; 148(9):2968-73. PubMed ID: 1374106
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Human renal cell carcinoma antigen-specific CTLs: antigen-driven selection and long-term persistence in vivo.
    Jantzer P; Schendel DJ
    Cancer Res; 1998 Jul; 58(14):3078-86. PubMed ID: 9679974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Analysis of T-cell receptor V region gene usage of cytotoxic T-lymphocytes and tumor-infiltrating lymphocytes derived from human autologous gastric signet ring cell carcinomas.
    Ikeda H; Sato N; Matsuura A; Kikuchi K
    Cancer Res; 1993 Jul; 53(13):3078-84. PubMed ID: 8391386
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Clinical results and characterization of tumor-infiltrating lymphocytes with or without recombinant interleukin 2 in human metastatic renal cell carcinoma.
    Bukowski RM; Sharfman W; Murthy S; Rayman P; Tubbs R; Alexander J; Budd GT; Sergi JS; Bauer L; Gibson V
    Cancer Res; 1991 Aug; 51(16):4199-205. PubMed ID: 1868441
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clonal analysis of lymphocytes from tumor, peripheral blood, and nontumorous kidney in primary renal cell carcinoma.
    Kim TY; von Eschenbach AC; Filaccio MD; Hayakawa K; Parkinson DR; Balch CM; Itoh K
    Cancer Res; 1990 Sep; 50(17):5263-8. PubMed ID: 2143685
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Restriction of the T-cell repertoire in tumor-infiltrating lymphocytes from nine patients with renal-cell carcinoma. Relevance of the CDR3 length analysis for the identification of in situ clonal T-cell expansions.
    Puisieux I; Bain C; Merrouche Y; Malacher P; Kourilsky P; Even J; Favrot M
    Int J Cancer; 1996 Apr; 66(2):201-8. PubMed ID: 8603812
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Evidence for local and systemic activation of immune cells by peritumoral injections of interleukin 2 in patients with advanced squamous cell carcinoma of the head and neck.
    Whiteside TL; Letessier E; Hirabayashi H; Vitolo D; Bryant J; Barnes L; Snyderman C; Johnson JT; Myers E; Herberman RB
    Cancer Res; 1993 Dec; 53(23):5654-62. PubMed ID: 8242620
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 36.